Please login to the form below

Not currently logged in

Roche acquires German diagnostics company Verum for €11m

Move is part of the Swiss pharma company's plans to build a comprehensive coagulation testing portfolio

Swiss pharma company Roche has acquired Verum Diagnostica for €11m as part of its plans to build a comprehensive coagulation testing portfolio.

Munich-based Verum is subsidiary of Dynabyte Informationssysteme and a leading company in platelet function testing, the fastest-growing field in the coagulation diagnostics market.

Colin Brown, head of Roche Professional Diagnostics, said: "Improving the assessment of a patient's platelet function status is currently a significant unmet need for haematologists, cardiologists and anaesthetists in order to support clinical decisions in cardiology, surgery and intensive care.

"With this acquisition we gain an innovative and unique platelet function testing solution which has the potential to set new standards of patient care in this area and perfectly complements our new coagulation portfolio."

Roche will pay €11m in cash for Verum Diagnostica, with a further €2m earmarked if certain performance-related milestones are reached.

The deal is expected to close in January, at which point Verum Diagnostica will become part of Roche's Professional Diagnostics business area.

Roche said the addition of Verum's platelet function testing technology would complement the line of coagulation analysers it plans to introduce in the US and Canada in 2014.

Aimed at the hospital and reference laboratory market these analysers will, subject to regulatory approval, allow Roche to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics.

Laboratory coagulation is estimated to be the fifth-largest market in professional diagnostics worldwide. Last year it was worth around $1.3bn USD and it's expected to see annual growth of 5.1% over the next five years.

6th December 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...